# China Life Investment Holding

> China Life Investment Holding is a VC fund in Beijing backing Manufacturing and Biopharma. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 9
- Last investment: May 2026
- Lead investor: 44%
- Last updated: Aug 2026
- Website: http://www.chinalifeinvest.com

China Life Investment Holding is an investment platform for China Life’s magnificent vision in healthcare sector, focusing on investment opportunities of premiu-quality companies along the industry chain of healthcare. It is committed to give full play to the driving role of commercial insurance, and deeply promote the integration and developmentof healthcare and insurance service, so as to meet diversified medical service and insurance protection demands of customers. Leveraging China Life’s massive resources, the Company can enrich portfolio companies’ customer base and provide insurance solutions integrally hence accelerating developments of portfolio companies. In addition, through cooperation and collaboration with portfolio companies, China Life can better serve its customers with premium-quality, convenient and integrated insurance, healthcare and medical solutions, and make a contribution to healthcare industry’s development and evolvement in China.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Manufacturing | 5 | 56% |
| Biopharma | 3 | 33% |
| Biotechnology | 2 | 22% |
| Semiconductor | 2 | 22% |
| Medical Device | 2 | 22% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 4 | 44% |
| Series D | 2 | 22% |
| Series B | 1 | 11% |
| Funding Round | 1 | 11% |
| Private Equity | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Volant Aerotech | Volant Aerotech is a company specializing in the R&D, manufacturing, and service of passenger eVTOL, an electric vertical take-off and landing aircraft. | $147.4M | Series C | May 27, 2026 |  |
| Shenzhen Energy Environmental Protection Co. | Shenzhen Energy Environmental Protection Co. is a waste disposal company providing research, engineering design, and operation management. | $691.7M |  | Mar 11, 2025 |  |
| Guizhou Core Long March Technology (Marching Power) | Core Long March Technology is a high-tech design company specializing in the development of new power semiconductor devices. Its core business includes: coolmos, SiC and other chip products and technology development. The technical team is based on the technical experts of the Chinese Academy of Sciences and the introduction of outstanding overseastechnical elites. The core members of the team have more than 6 years of product development experience, and realize the whole chain from chip design, manufacturing process, packaging and testing, reliability and application. The company has a professional marketing and operation management team. It is very familiar with the technology, industry and market in this direction and has good operational capabilities. The technical and management teams have gone through the process from technology development to sample to product to mass production to complete marketization. . |  | Series D | Jan 09, 2023 |  |
| Eswin | Eswin provides IC application solutions in mobile devices, smart homes, smart transportation, industrial IoT, produces 12-inch monocrystalline silicon polished wafers and epitaxial wafers, and delivers rear-end IC packaging and testing services, according to its website. It operates R&D centers in China, the U.K., and South Korea, and hasproduction facilities in Xi'an, Chengdu, Hefei and Suzhou. | $567M | Series C | Dec 09, 2022 |  |
| Eswin Materials | Eswin Materials manufactures electronic-grade silicon single crystal polished wafers and epitaxial wafers for electronic and EV industries. | $574.9M | Series C | Dec 09, 2022 |  |
| Taibang Biological Group | China Biologic Products Holdings, Inc. (NASDAQ: CBPO), is a leading fully integrated plasma-based biopharmaceutical company in China. Their core capabilities include plasma collection, research and development, manufacturing, and commercialization of human plasma-based biopharmaceutical products. Their company was founded in 2002 and was listed onNASDAQ in 2009.Their products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. Backed by robust research and development capabilities, they aim to capture substantially all of the value along the plasma products value chain, and to develop their technology to enhance life quality and create value for more patients. They have expanded their product portfolio to eight categories of plasma-based products, including human albumin, immunoglobulin for intravenous injection and coagulation factor products, as well as other biopharmaceutical products, and they continue to make progress on new pipeline products. | $300M | Private Equity | Aug 02, 2022 |  |
| METiS Pharmaceuticals | METiS Pharmaceuticals is the world's first AI-driven drug formulation company. | $150M | Series B | Apr 06, 2022 |  |
| SiBionics | SiBionics is a medtech specialized in R&D & commercialization of implantable medical devices and medical imaging artificial intelligence. | $126M | Series C | Jan 21, 2022 |  |
| Innovent Biologics | Innovent Biologics, Inc. is a privately held biopharmaceutical company that is dedicated to the development and manufacturing of monoclonal antibodies to be marketed in China and elsewhere around the world. Innovent is funded by the venture arm of Fidelity, which is a major investment firm in the US, Lilly Ventures, and Suzhou bioBay. Theregistered capital is 30Million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development and manufacture of biologics in the US, Europe and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others. | $260M | Series D | Nov 29, 2016 |  |

9 of 9 investments shown.

## Co-investors
- [Source Code Capital](https://shizune.co/investors/profile/source-code-capital) — VC Fund, 3 deals together
- [China Development Bank Capital](https://shizune.co/investors/profile/china-development-bank-capital) — VC Fund, 2 deals together
- China National Building Material — VC Fund, 2 deals together
- [Chongqing Yufu Holding Group](https://shizune.co/investors/profile/chongqing-yufu-holding-group) — VC Fund, 2 deals together
- [GF Venture Capital](https://shizune.co/investors/profile/gf-venture-capital) — VC Fund, 2 deals together
- [Hongsheng Capital](https://shizune.co/investors/profile/hongsheng-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does China Life Investment Holding invest in?

China Life Investment Holding invests primarily in Manufacturing, Biopharma and Biotechnology startups, most often at Series C and Series D stage. Most of the 9 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did China Life Investment Holding last invest?

The most recent investment recorded for China Life Investment Holding closed in May 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co